Five-Year Healthcare Utilization and Costs Among Lower-Risk Drinkers Following Alcohol Treatment
Andrea H. Kline-Simon,Constance Weisner,Constance Weisner,Sujaya Parthasarathy,Daniel E. Falk,Raye Z. Litten,Jennifer R. Mertens +6 more
Reads0
Chats0
TLDR
Performance measures for treatment settings that consider treatment outcomes may need to take into account both abstinence and reduction to nonheavy drinking, as well as healthcare utilization and costs over 5 years.Abstract:
BACKGROUND: Lower-risk drinking is increasingly being examined as a treatment outcome for some patients following addiction treatment. However, few studies have examined the relationship between drinking status (lower-risk drinking in particular) and healthcare utilization and cost, which has important policy implications. METHODS: Participants were adults with alcohol dependence and/or abuse diagnoses who received outpatient alcohol and other drug treatment in a private, nonprofit integrated healthcare delivery system and had a follow-up interview 6 months after treatment entry (N = 995). Associations between past 30-day drinking status at 6 months (abstinence, lower-risk drinking defined as nonabstinence and no days of 5+ drinking, and heavy drinking defined as 1 or more days of 5+ drinking) and repeated measures of at least 1 emergency department (ED), inpatient or primary care visit, and their costs over 5 years were examined using mixed-effects models. We modeled an interaction between time and drinking status to examine trends in utilization and costs over time by drinking group. RESULTS: Heavy drinkers and lower-risk drinkers were not significantly different from the abstainers in their cost or utilization at time 0 (i.e., 6 months postintake). Heavy drinkers had increasing odds of inpatient (p CONCLUSIONS: Performance measures for treatment settings that consider treatment outcomes may need to take into account both abstinence and reduction to nonheavy drinking. Future research should examine whether results are replicated in harm reduction treatment, or whether such outcomes are found only in abstinence-based treatment. Language: enread more
Citations
More filters
Journal ArticleDOI
Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels
Katie Witkiewitz,Kevin A. Hallgren,Henry R. Kranzler,Karl Mann,Deborah S. Hasin,Daniel E. Falk,Raye Z. Litten,Stephanie S. O'Malley,Raymond F. Anton +8 more
TL;DR: Changes in WHO risk levels appear to be a valid end point for alcohol clinical trials and reflect meaningful reductions in alcohol‐related consequences and improved functioning.
Journal ArticleDOI
Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.
Katie Witkiewitz,Henry R. Kranzler,Kevin A. Hallgren,Stephanie S. O'Malley,Daniel E. Falk,Raye Z. Litten,Deborah S. Hasin,Karl Mann,Raymond F. Anton +8 more
TL;DR: One- and two-level reductions in World Health Organization drinking risk levels predicted significant improvements in markers of physical health and quality of life, suggesting that the WHO drinking risk level reduction could be a meaningful surrogate marker of improvements in how a person "feels and functions" following treatment for alcohol dependence.
Journal ArticleDOI
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Daniel E. Falk,Stephanie S. O'Malley,Katie Witkiewitz,Raymond F. Anton,Raye Z. Litten,Megan Slater,Henry R. Kranzler,Karl Mann,Deborah S. Hasin,Bankole A. Johnson,Didier Meulien,Megan L. Ryan,Joanne B. Fertig +12 more
TL;DR: WHO drinking risk level reductions appear to be worthwhile indicators of treatment outcome in AUD pharmacotherapy trials and may align with drinking reduction goals of many patients and capture clinically meaningful improvements experienced by more patients than either abstinence or no heavy drinking days.
Journal ArticleDOI
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety.
Daniel E. Falk,Megan L. Ryan,Joanne B. Fertig,Eric Devine,Ricardo Cruz,E. Sherwood Brown,Heather Burns,Ihsan M. Salloum,D. Jeffrey Newport,John Mendelson,Gantt P. Galloway,Kyle M. Kampman,Catherine Brooks,Alan I. Green,Mary F. Brunette,Richard N. Rosenthal,Richard N. Rosenthal,Kelly E. Dunn,Eric C. Strain,Lara A. Ray,Steven Shoptaw,Nassima Ait-Daoud Tiouririne,Erik W. Gunderson,Janet Ransom,Charles Scott,Lorenzo Leggio,Steven Caras,Barbara J. Mason,Raye Z. Litten +28 more
TL;DR: It is possible that, unlike the IR formulation of gabapentin, which showed efficacy in smaller Phase 2 trials at a higher dose, GE-XR is not effective in treating AUD, at least not at doses approved by the U.S. Food and Drug Administration for treating other medical conditions.
Journal ArticleDOI
Liver transplantation in patients with alcohol-related liver disease: current status and future directions.
TL;DR: Data accumulated since 2011 suggest that early liver transplantation (ie, transplantation without a specific period of abstinence) in patients with severe alcoholic hepatitis who do not respond to medical therapy is an effective therapeutic strategy.
References
More filters
Journal ArticleDOI
The fifth edition of the addiction severity index
A. Thomas McLellan,Harvey Kushner,David S. Metzger,Roger H. Peters,Iris E. Smith,Grant R. Grissom,Helen M. Pettinati,Milton Argeriou +7 more
TL;DR: The clinical and research uses of the ASI over the past 12 years are discussed, emphasizing some special circumstances that affect its administration.
Journal ArticleDOI
Smearing Estimate: A Nonparametric Retransformation Method
TL;DR: The smearing estimate as discussed by the authors is a nonparametric estimate of the expected response on the untransformed scale after fitting a linear regression model on a transformed scale, which is consistent under mild regularity conditions, and usually attains high efficiency relative to parametric estimates.
Journal ArticleDOI
The “Meaningful Use” Regulation for Electronic Health Records
TL;DR: The widespread use of electronic health records (EHRs) in the United States is inevitable, but inevitability does not mean easy transition.
Posted Content
Generalized Modeling Approaches to Risk Adjustment of Skewed Outcomes Data
TL;DR: This paper encompasses these two classes of models using the three parameter generalized Gamma (GGM) distribution, which includes several of the standard alternatives as special cases-OLS with a normal error, OLS for the log-normal, the standard Gamma and exponential with a log link, and the Weibull.
Journal ArticleDOI
Generalized Modeling Approaches to Risk Adjustment of Skewed Outcomes Data
TL;DR: In this article, the authors use the generalized gamma distribution (GGM) as a robust alternative estimator to the standard OLS with a normal error, OLS for the log-normal, the standard Gamma and exponential with a log link, and Weibull.
Related Papers (5)
Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population.
Deborah S. Hasin,Melanie M. Wall,Katie Witkiewitz,Henry R. Kranzler,Henry R. Kranzler,Daniel E. Falk,Raye Z. Litten,Karl Mann,Stephanie S. O'Malley,Jennifer Scodes,Rebecca L. Robinson,Raymond F. Anton,Joanne B. Fertig,Keith Isenberg,David J. McCann,Didier Meulien,Roger E. Meyer,Charles A. O'Brien,Megan L. Ryan,Bernard L. Silverman,Francoise Trinquet,Conrad J. Wong,Benjamine Zakine +22 more